Showing 2701-2710 of 9959 results for "".
FDA Grants Interchangeability to HADLIMA
https://practicaldermatology.com/series/dermwire-tv/fda-grants-interchangeability-to-hadlima/35962/In this week's DermwireTV, the FDA grants full interchangeability to HADLIMA; new research shows the impact of UV exposure on global skin cancer cases; and coverage from Music City SCALE addresses barriers to patient access to new therapies.Fractional Lasers for NMSC and More
https://practicaldermatology.com/conferences/scale-2025/fractional-lasers-for-nmsc-and-more/35876/Joel L. Cohen, MD, FAAD, and Matthew M. Avram, MD, talk about research involving fractional lasers, including as part of combination treatments for nonmelanoma skin cancer, at Music City SCALE 2025.Advances in Hair Loss Treatments
https://practicaldermatology.com/conferences/scale-2025/advances-in-hair-loss-treatments/35899/Marc R. Avram, MD, talks at Music City SCALE 2025 about hair loss and advances in platelet-rich plasma (PRP), lasers, and transplantation.Medical Dermatology Highlights
https://practicaldermatology.com/programs/practical-dermatology/medical-dermatology-highlights/35889/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, summarizes the various medical dermatology sessions he presented at Music City SCALE 2025.Procedural Management for HS
https://practicaldermatology.com/programs/practical-dermatology/procedural-management-for-hs/35891/Vivian Shi, MD, talks about procedural management for hidradenitis suppurativa and how to incorporate those procedures with medical management of the condition at Music City SCALE 2025.DWTV Extra: New Tapinarof Data for AD
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-new-tapinarof-data-for-ad/33940/Linda Stein Gold, MD, discusses the results from the Phase 3 ADORING 3 open-label, long-term extension study evaluating tapinarof cream, 1% once daily in children as young as 2 and adults with atopic dermatitis, presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in OrlandoDr. Anderson on New Tech That ‘Could be Revolutionary’ at Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/dr-anderson-on-new-tech-that-could-be-revolutionary-at-maui-derm/32921/In-vivo microscopy that will change how dermatologists practice and potentially revolutionary drug delivery systems were among the technologies highlighted by R. Rox Anderson, MD, PhD, during “Innovation in Dermatology 2025: A Look Into the Future of Dermatology” at the Maui Derm Hawaii 2025 meetingMaui Derm Panel: GLP-1 Agonists Can Help Psoriasis Patients
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/maui-derm-panel-glp-1-agonists-can-help-psoriasis-patients/32917/Only 11% of Maui Derm 2025 audience members polled said they were comfortable prescribing weight-loss drugs, and 49% said they were not at all—but they should be, according to the presenters of “Psoriasis Update 2025” at the conference in Maui, Hawaii.Journal Club: Dupilumab and Risk of Malignancy
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national databaseEczematous Dermatitis: Dr. Zirwas
https://practicaldermatology.com/programs/practical-dermatology/eczematous-dermatitis-dr-zirwas/32689/Matthew Zirwas, MD, talks about the therapeutic strategies for non-atopic dermatitis—particularly hand dermatitis and facial dermatitis—that he covered during "Eczematous Dermatitis Update 2025: Contact, Hand, Head and Neck, Eyelid and More" at Maui Derm 2025.